These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24245693)

  • 1. Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.
    Kanakkanthara A; Eras J; Northcote PT; Cabral F; Miller JH
    Curr Cancer Drug Targets; 2014; 14(1):79-90. PubMed ID: 24245693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
    Kanakkanthara A; Wilmes A; O'Brate A; Escuin D; Chan A; Gjyrezi A; Crawford J; Rawson P; Kivell B; Northcote PT; Hamel E; Giannakakou P; Miller JH
    Mol Cancer Ther; 2011 Aug; 10(8):1419-29. PubMed ID: 21653684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
    Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
    Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A; Northcote PT; Miller JH
    Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells.
    Kanakkanthara A; Rawson P; Northcote PT; Miller JH
    Pharm Res; 2012 Nov; 29(11):3022-32. PubMed ID: 22584948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.
    Gaitanos TN; Buey RM; Díaz JF; Northcote PT; Teesdale-Spittle P; Andreu JM; Miller JH
    Cancer Res; 2004 Aug; 64(15):5063-7. PubMed ID: 15289305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.
    Zúñiga MA; Alderete JB; Jaña GA; Jiménez VA
    J Comput Aided Mol Des; 2017 Jul; 31(7):643-652. PubMed ID: 28597356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.
    Begaye A; Trostel S; Zhao Z; Taylor RE; Schriemer DC; Sackett DL
    Cell Cycle; 2011 Oct; 10(19):3387-96. PubMed ID: 21926482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae.
    Hanna R; Maass DR; Atkinson PH; Northcote PT; Teesdale-Spittle PH; Bellows DS; Miller JH
    Mol Biosyst; 2014 Jan; 10(1):110-6. PubMed ID: 24161989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
    Wilmes A; O'Sullivan D; Chan A; Chandrahasen C; Paterson I; Northcote PT; La Flamme AC; Miller JH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):117-26. PubMed ID: 20848285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zampanolide, a Microtubule-Stabilizing Agent, Is Active in Resistant Cancer Cells and Inhibits Cell Migration.
    Field JJ; Northcote PT; Paterson I; Altmann KH; Díaz JF; Miller JH
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
    Wang Y; O'Brate A; Zhou W; Giannakakou P
    Cell Cycle; 2005 Dec; 4(12):1847-53. PubMed ID: 16294009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of lateral and longitudinal interdimeric interactions in microtubule models by Laulimalide and Peloruside A association: A molecular modeling approach on the mechanism of microtubule stabilizing agents.
    Zúñiga MA; Alderete JB; Jaña GA; Fernandez PA; Ramos MJ; Jiménez VA
    Chem Biol Drug Des; 2018 May; 91(5):1042-1055. PubMed ID: 29316292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the interaction of Peloruside-A with drug resistant αβII and αβIII tubulin isotypes in human ovarian carcinoma using a molecular modeling approach.
    Kumbhar BV; Bhandare VV
    J Biomol Struct Dyn; 2021 Apr; 39(6):1990-2002. PubMed ID: 32241247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
    Wilmes A; Bargh K; Kelly C; Northcote PT; Miller JH
    Mol Pharm; 2007; 4(2):269-80. PubMed ID: 17397239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.
    Hamel E; Day BW; Miller JH; Jung MK; Northcote PT; Ghosh AK; Curran DP; Cushman M; Nicolaou KC; Paterson I; Sorensen EJ
    Mol Pharmacol; 2006 Nov; 70(5):1555-64. PubMed ID: 16887932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular effects of the microtubule-targeting agent peloruside A in hypoxia-conditioned colorectal carcinoma cells.
    Řehulka J; Annadurai N; Frydrych I; Znojek P; Džubák P; Northcote P; Miller JH; Hajdúch M; Das V
    Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1833-1843. PubMed ID: 28366502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A.
    Nguyen TL; Xu X; Gussio R; Ghosh AK; Hamel E
    J Chem Inf Model; 2010 Nov; 50(11):2019-28. PubMed ID: 21028850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peloruside, laulimalide, and noscapine interactions with beta-tubulin.
    Gajewski MM; Alisaraie L; Tuszynski JA
    Pharm Res; 2012 Nov; 29(11):2985-93. PubMed ID: 22733149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.